Evidence map›Paper›PMID 36718802›Full record

ArticleCardiovascular research2023

Human and murine fibroblast single-cell transcriptomics reveals fibroblast clusters are differentially affected by ageing and serum cholesterol.

Kim van Kuijk, Ian R McCracken, Renée J H A Tillie, Sebastiaan E J Asselberghs, Dlzar A Kheder, Stan Muitjens, Han Jin, Richard S Taylor, Ruud Wichers Schreur, Christoph Kuppe and 18 more

Open access · hybridAbstract read
In one paragraph

Article in Cardiovascular research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
6.1field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 37 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Review
  6. KRAS inhibition is an effective therapy for appendiceal adenocarcinoma.bioRxiv : the preprint server for biology · 2026
    Article
  7. Article
  8. Tenascin CNature communications · 2026
    Article
  9. Review
  10. Article
  11. Single-Cell Multimodal Profiling Reveals a Novel CD26Arteriosclerosis, thrombosis, and vascular biology · 2025
    Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Promising Adventitia in Atherosclerosis.Current vascular pharmacology · 2025
    Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

28 authors at 7 institutions in 4 countries.

Kim van KuijkCardiovascular Research Institute Maastricht (CARIM), Maastricht University Medical Center, PO Box 5800, 6202 AZ Maastricht, The Netherlands.ORCID 0000-0001-8880-9039
Ian R McCrackenBHF Centre for Cardiovascular Sciences (CVS), Queen's Medical Research Institute, University of Edinburgh, 47 Little France Crescent, Edinburgh EH16 4TJ, UK.ORCID 0000-0001-8806-548X
Renée J H A TillieCardiovascular Research Institute Maastricht (CARIM), Maastricht University Medical Center, PO Box 5800, 6202 AZ Maastricht, The Netherlands.ORCID 0000-0002-0648-4304
Sebastiaan E J AsselberghsCardiovascular Research Institute Maastricht (CARIM), Maastricht University Medical Center, PO Box 5800, 6202 AZ Maastricht, The Netherlands.ORCID 0000-0002-8983-5359
Dlzar A KhederCardiovascular Research Institute Maastricht (CARIM), Maastricht University Medical Center, PO Box 5800, 6202 AZ Maastricht, The Netherlands.ORCID 0000-0002-6688-4537
Stan MuitjensCardiovascular Research Institute Maastricht (CARIM), Maastricht University Medical Center, PO Box 5800, 6202 AZ Maastricht, The Netherlands.
Han JinCardiovascular Research Institute Maastricht (CARIM), Maastricht University Medical Center, PO Box 5800, 6202 AZ Maastricht, The Netherlands.ORCID 0000-0002-0955-6289
Richard S TaylorBHF Centre for Cardiovascular Sciences (CVS), Queen's Medical Research Institute, University of Edinburgh, 47 Little France Crescent, Edinburgh EH16 4TJ, UK.
Ruud Wichers SchreurCardiovascular Research Institute Maastricht (CARIM), Maastricht University Medical Center, PO Box 5800, 6202 AZ Maastricht, The Netherlands.
Christoph KuppeInstitute of Experimental Medicine and Systems Biology, Faculty of Medicine, RWTH Aachen University, Aachen, Germany.ORCID 0000-0003-4597-9833
Ross DobieCentre for Inflammation Research, University of Edinburgh, Edinburgh, UK.ORCID 0000-0001-9516-315X
Prakesh RamachandranDepartment of Medical Biochemistry, Experimental Vascular Biology, Amsterdam UMC, Amsterdam, The Netherlands.ORCID 0000-0001-5996-2413
Marion J GijbelsCardiovascular Research Institute Maastricht (CARIM), Maastricht University Medical Center, PO Box 5800, 6202 AZ Maastricht, The Netherlands.ORCID 0000-0002-4906-0384
Lieve TemmermanCardiovascular Research Institute Maastricht (CARIM), Maastricht University Medical Center, PO Box 5800, 6202 AZ Maastricht, The Netherlands.ORCID 0000-0003-1102-0640
Phoebe M KirkwoordCentre for Inflammation Research, University of Edinburgh, Edinburgh, UK.ORCID 0000-0002-5245-718X
Joris LuytenCardiovascular Research Institute Maastricht (CARIM), Maastricht University Medical Center, PO Box 5800, 6202 AZ Maastricht, The Netherlands.
Yanming LiDivision of Cardiothoracic Surgery, Baylor College of Medicine, Houston, TX, USA.ORCID 0000-0002-8213-9166
Heidi NoelsCardiovascular Research Institute Maastricht (CARIM), Maastricht University Medical Center, PO Box 5800, 6202 AZ Maastricht, The Netherlands.ORCID 0000-0003-3053-6984
Pieter GoossensCardiovascular Research Institute Maastricht (CARIM), Maastricht University Medical Center, PO Box 5800, 6202 AZ Maastricht, The Netherlands.ORCID 0000-0002-7269-6372
John R Wilson-KanamoriDivision of Nephrology and Clinical Immunology, Faculty of Medicine, RWTH Aachen University, Aachen, Germany.ORCID 0000-0002-1372-9912
Leon J SchurgersCardiovascular Research Institute Maastricht (CARIM), Maastricht University Medical Center, PO Box 5800, 6202 AZ Maastricht, The Netherlands.ORCID 0000-0001-7867-6957
Ying H ShenDivision of Cardiothoracic Surgery, Baylor College of Medicine, Houston, TX, USA.
Barend M E MeesCardiovascular Research Institute Maastricht (CARIM), Maastricht University Medical Center, PO Box 5800, 6202 AZ Maastricht, The Netherlands.ORCID 0000-0001-6545-5813
Erik A L BiessenCardiovascular Research Institute Maastricht (CARIM), Maastricht University Medical Center, PO Box 5800, 6202 AZ Maastricht, The Netherlands.ORCID 0000-0002-6454-8548
Neil C HendersonDivision of Nephrology and Clinical Immunology, Faculty of Medicine, RWTH Aachen University, Aachen, Germany.ORCID 0000-0002-2273-4094
Rafael KramannInstitute of Experimental Medicine and Systems Biology, Faculty of Medicine, RWTH Aachen University, Aachen, Germany.ORCID 0000-0003-4048-6351
Andrew H BakerCardiovascular Research Institute Maastricht (CARIM), Maastricht University Medical Center, PO Box 5800, 6202 AZ Maastricht, The Netherlands.ORCID 0000-0003-1441-5576
Judith C SluimerCardiovascular Research Institute Maastricht (CARIM), Maastricht University Medical Center, PO Box 5800, 6202 AZ Maastricht, The Netherlands.ORCID 0000-0002-0269-4582
University Medical Center · USCentre for Inflammation Research · GBBaylor College of Medicine · USRWTH Aachen University · DEThe Queen's Medical Research Institute · GBInstitute of Genetics and Cancer · GBMaastricht University · NL

Funding

Pro-inflammatory Pyroptotic Cell Death in Aortic DegenerationR01HL158157 · NHLBI · BAYLOR COLLEGE OF MEDICINE · PI LEMAIRE, SCOTT A, SHEN, YING H · 2021 to 2024
$2.4M
British Heart Foundation CH/11/2/28733British Heart Foundation RG/14/3/30706British Heart Foundation RG/20/5/34796Medical Research Council MR/N008340/1Medical Research Council MR/W015919/1NHLBI NIH HHS R01 HL158157Wellcome TrustWellcome Trust 219542/Z/19/Z
6 · The paper itself

Abstract

aimsSpecific fibroblast markers and in-depth heterogeneity analysis are currently lacking, hindering functional studies in cardiovascular diseases (CVDs). Here, we established cell-type markers and heterogeneity in murine and human arteries and studied the adventitial fibroblast response to CVD and its risk factors hypercholesterolaemia and ageing. METHODS AND

resultsMurine aorta single-cell RNA-sequencing analysis of adventitial mesenchymal cells identified fibroblast-specific markers. Immunohistochemistry and flow cytometry validated platelet-derived growth factor receptor alpha (PDGFRA) and dipeptidase 1 (DPEP1) across human and murine aorta, carotid, and femoral arteries, whereas traditional markers such as the cluster of differentiation (CD)90 and vimentin also marked transgelin+ vascular smooth muscle cells. Next, pseudotime analysis showed multiple fibroblast clusters differentiating along trajectories. Three trajectories, marked by CD55 (Cd55+), Cxcl chemokine 14 (Cxcl14+), and lysyl oxidase (Lox+), were reproduced in an independent RNA-seq dataset. Gene ontology (GO) analysis showed divergent functional profiles of the three trajectories, related to vascular development, antigen presentation, and/or collagen fibril organization, respectively. Trajectory-specific genes included significantly more genes with known genome-wide associations (GWAS) to CVD than expected by chance, implying a role in CVD. Indeed, differential regulation of fibroblast clusters by CVD risk factors was shown in the adventitia of aged C57BL/6J mice, and mildly hypercholesterolaemic LDLR KO mice on chow by flow cytometry. The expansion of collagen-related CXCL14+ and LOX+ fibroblasts in aged and hypercholesterolaemic aortic adventitia, respectively, coincided with increased adventitial collagen. Immunohistochemistry, bulk, and single-cell transcriptomics of human carotid and aorta specimens emphasized translational value as CD55+, CXCL14+ and LOX+ fibroblasts were observed in healthy and atherosclerotic specimens. Also, trajectory-specific gene sets are differentially correlated with human atherosclerotic plaque traits.

conclusionWe provide two adventitial fibroblast-specific markers, PDGFRA and DPEP1, and demonstrate fibroblast heterogeneity in health and CVD in humans and mice. Biological relevance is evident from the regulation of fibroblast clusters by age and hypercholesterolaemia in vivo, associations with human atherosclerotic plaque traits, and enrichment of genes with a GWAS for CVD.

Indexed as

AtherosclerosisHypercholesterolemiaPlaque, AtheroscleroticAgedAgingAnimalsCholesterolCollagenFibroblastsHumansMiceMice, Inbred C57BLReceptor Protein-Tyrosine KinasesTranscriptomeCholesterolCollagenReceptor Protein-Tyrosine KinasesAdventitiaAtherosclerosisFibroblastsHeterogeneitySingle-cell RNA-seq

Identifiers

PMID36718802
PMCPMC10318398
OpenAlexW4318668422

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.